Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis

Hypertension

Volumn 51, Issue 2, 2008, Pages 252-258

  Li, Ping ^a   Kondo, Takahisa ^a   Numaguchi, Yasushi ^a   Kobayashi, Koichi ^a   Aoki, Mika ^a   Inoue, Natsuo ^a   Okumura, Kenji ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Angiotensin II; Angiotensin converting enzyme; Bradykinin; Ischemia; Microcirculation; NO

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BRADYKININ; IMIDAPRIL; NITRIC OXIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DOPPLER FLOWMETRY; DRUG MECHANISM; KNOCKOUT MOUSE; LIMB ISCHEMIA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANGIOGENESIS INDUCING AGENTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; CAPILLARIES; ENZYME INHIBITORS; HINDLIMB; IMIDAZOLES; IMIDAZOLIDINES; ISCHEMIA; MALE; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 38549151187     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.097394     Document Type: Article

References (34)

1. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441- 449.
2. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651- 657.
3. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996;27:760-765.
4. Le Noble FA, Schreurs NH, van Straaten HW, Slaaf DW, Smits JF, Rogg H, Struijker-Boudier HA. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol. 1993;264:460-465.
5. Walsh DA, Hu DE, Wharton J, Catravas JD, Blake DR, Fan TP. Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma. Br J Pharmacol. 1997;120:1302-1311.
6. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, Imaizumi T. Evidence for the importance of angiotensin II type I receptor in ischemia-induced angiogenesis. J Clin Invest. 2001;109:603-611.
7. Egami K, Murohara T, shimada T, Sasaki K, Shintani S. Role of host angiotensin II type I receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67-75.
8. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 1997;29:478-482.
9. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia. 1992;34:12-18.
10. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 1999;99:3043-3049.
11. Morbidelli L, Parenti A, Giovannelli L, Granger HJ, Ledda F, Ziche M. B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br J Pharmacol. 1998;124:1286 -1292.
12. 9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br J Pharmacol. 1993;109:14-17.
13. Emanueli C, Zacheo A, Minasi A, Chao J, Chao L, Salis MB, Stacca T, Straino S, Capogrossi MC, Madeddu P. Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol. 2000;20:2379-2385.
14. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC, Madeddu P. Local delivery of human tissue kallikrein gene accelarates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001;103:125-132.
15. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567-2578.
16. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667-1679.
17. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun. 2002;294:441-447.
18. Hiratsuka S, Nakao K, Nakamura K, Katsuki M, Maru Y, Shibuya M. Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice. Mol Cell Biol. 2005;25:346-354.
19. Raymond J, Lebel V, Ogoudikpe C, Metcalfe A, Chagnon M, Robledo O. Recanalization of arterial thrombus, and inhibition with beta-radiation in a new murine carotid occlusion model: MRNA expression of angiopoietins, metalloproteinases, and their inhibitors. J Vasc Surg. 2004;40:1190-1198.
20. Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest. 2004;114:1317-1325.
21. Su JB, Hoüel R, Héloire F, Barbe F, Beverelli F, Sambin L, Castaigne A, Berdeaux A, Crozatier B, Hittinger L. Stimulation of bradykinin B1 receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs. Comparison with B2 receptor stimulation. Circulation. 2000;101:1848-1853.
22. Schanstra JP, Marin-Castano ME, Praddaude F, Tack I, Ader JL, Girolami JP, Bascands JL. Bradykinin B1 receptor-mediated changes in renal hemodynamics during endotoxin-induced inflammation. J Am Soc Nephrol. 2000;11:1208-1215.
23. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradykinin/ B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001;15:1487-1489.
24. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger C, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B2 receptor pathway. Circ Res. 2001;89:678-683.
25. Chen R, Iwai M, Wu L, Suzuki J, Min LJ, Shiuchi T, Sugaya T, Liu HW, Cui TX. Horiuchi M. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension. 2003;42:542-547.
26. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, Pinna A, Gaspa L, Regoli D, Cayla C, Pesquero JB, Bader M, Madeddu P. Targeting kinin B1 receptor for therapeutic neovascularization. Circulation. 2002;105:360-366.
27. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998;31:349-355.
28. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahara H, Iwasaka T. Angiotensin II type 2 receptor overexpression activate the vascular kinin system and cause vasodilation. J Clin Invest. 1999;104:925-935.
29. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, Amano K, Matsubara H. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension. 2003;41:99-107.
30. Bergara S, Hilgers RHP, Meneton P, Dong Y, Bloch-Faure M, Inagami T, Alhenc-Gelas F, Levy BI, Boulanger C. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res. 2004;94:1623-1629.
31. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem. 2002;277:2028-2032.
32. Miura S, Matsuo M, Saku S. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension. 2003;41:1118-1123.
33. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
34. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.